Document is current
Any future updates will be listed below
-
Authors
Tubío-Santamaría, Nuria
Jayavelu, Ashok Kumar
Schnoeder, Tina M.
Eifert, Theresa
Hsu, Chen-Jen
Perner, Florian
Zhang, Qirui
Wenge, Daniela V.
Hansen, Fynn M.
Kirkpatrick, Joanna M.
Jyotsana, Nidhi
Lane, Steven W.
von Eyss, Björn
Deshpande, Aniruddha J.
Kühn, Michael W. M.
Schwaller, Juerg
Cammann, Clemens
Seifert, Ulrike
Ebstein, Frédéric
Krüger, Elke
Hochhaus, Andreas
Heuser, Michael
Ori, Alessandro
Mann, Matthias
Armstrong, Scott A.
Heidel, Florian H.
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (HE6233/8-1)
Wilhelm Sander-Stiftung (2019.001.01)
Universität Greifswald
- License Information
-
More Information
Article History
Received: 17 June 2023
Accepted: 21 November 2023
First Online: 4 December 2023
Declarations
:
: Primary AML patient samples and healthy donor controls were obtained after informed consent and according to the Helsinki declaration within the AML-trials of the German-Austrian AMLSG study group and from the Hematology Tumor Bank Jena and Magdeburg, approved by the respective local ethics committee (Ethics Committee of the Medical Faculty, University Hospital Jena #4753/04–16 or University Hospital Magdeburg #115/08).All mice were housed under pathogen-free conditions in the Animal Research Facility of the Otto-von-Guericke University Medical Faculty Magdeburg, the ZET (University Hospital Jena) and ZTL (University Medicine Greifswald). All experiments were conducted after approval by the respective authorities of Sachsen-Anhalt (42502–2-1279 UniMD), Thüringen (02–030/2016) and Mecklenburg-Vorpommern (7221.3–1-019/22).
: S.A.A., M.W.M.K., F.P.: Advisors to Syndax Inc. Otherwise, the authors declare no competing interests.
